NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said today that it will collaborate with the Newman-Lakka Institute for Personalized Cancer Care at Floating Hospital for Children at Tufts Medical Center on methods for detecting and tracking blood-based protein biomarkers for various cancers.

The work will focus on applying the company's liquid chromatography-mass spectrometry equipment along with its mass spectrometry immunoassay technology to identify markers for breast and prostate cancer as well as tumor-associated blood vessel formation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Patients who've learned their genetic risk of disease worry about healthcare law changes in the US, Kaiser Health News reports.

Hopkins' Geoffrey Ling discusses the promise of genomic vaccines at Scientific American.

In Nature this week: mitochondrial genome of extinct South American ungulate, and more.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.